- Home
- JWEL vs DRMA Comparison
JWEL vs DRMA Comparison
Compare JWEL & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JWEL
- DRMA
- Stock Information
- Founded
- JWEL 2012
- DRMA 2014
- Country
- JWEL China
- DRMA United States
- Employees
- JWEL N/A
- DRMA N/A
- Industry
- JWEL Other Consumer Services
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- JWEL Consumer Discretionary
- DRMA Health Care
- Exchange
- JWEL Nasdaq
- DRMA Nasdaq
- Market Cap
- JWEL 3.9M
- DRMA 4.5M
- IPO Year
- JWEL 2021
- DRMA 2021
- Fundamental
- Price
- JWEL $1.71
- DRMA $0.73
- Analyst Decision
- JWEL
- DRMA Strong Buy
- Analyst Count
- JWEL 0
- DRMA 1
- Target Price
- JWEL N/A
- DRMA $6.00
- AVG Volume (30 Days)
- JWEL 4.0K
- DRMA 4.3M
- Earning Date
- JWEL 05-12-2025
- DRMA 05-14-2025
- Dividend Yield
- JWEL N/A
- DRMA N/A
- EPS Growth
- JWEL N/A
- DRMA N/A
- EPS
- JWEL N/A
- DRMA N/A
- Revenue
- JWEL $160,009,293.00
- DRMA N/A
- Revenue This Year
- JWEL N/A
- DRMA N/A
- Revenue Next Year
- JWEL N/A
- DRMA N/A
- P/E Ratio
- JWEL N/A
- DRMA N/A
- Revenue Growth
- JWEL N/A
- DRMA N/A
- 52 Week Low
- JWEL $1.00
- DRMA $0.70
- 52 Week High
- JWEL $3.71
- DRMA $6.17
- Technical
- Relative Strength Index (RSI)
- JWEL 31.74
- DRMA 28.13
- Support Level
- JWEL $1.77
- DRMA $0.72
- Resistance Level
- JWEL $2.14
- DRMA $0.89
- Average True Range (ATR)
- JWEL 0.13
- DRMA 0.10
- MACD
- JWEL 0.01
- DRMA -0.03
- Stochastic Oscillator
- JWEL 7.53
- DRMA 5.92
About JWEL Jowell Global Ltd.
Jowell Global Ltd is a cosmetics, health and nutritional supplements, and household products e-commerce platform. It operates under Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing sales channels. The company's major merchandise categories are Cosmetic products, Health and nutritional supplements, and Household Products.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc. is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.